KRN7000 being investigated in cancer research:

Colorectal cancer research

Head and neck tumor research

Leukemia research

Lung cancer research

Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand

Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide

KRN7000, a novel immunomodulator, and its antitumor activities

Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity

Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model

Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma

Antitumor Effect of Alpha-Galactosylceramide (KRN7000) on Spontaneous Hepatic Metastases Requires Endogenous Interleukin 12 in the Liver

Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation

The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy

Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity

Alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors

Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells

Alpha-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis

Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice

Invariant natural killer T cell-based immunotherapy for cancer

Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma

Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo

Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells

Modulation of human Valpha24(+)Vbeta11(+) NKT cells by age, malignancy and conventional anticancer therapies

Harnessing CD1d-restricted T cells toward antitumor immunity in humans

Natural killer T cell-mediated antitumor immune responses and their clinical applications

Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells

Cutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with Alpha-Galactosylceramide

Effects of a-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on
phenotype and cytokine pro®le of human Va24+ Vb11+ T cells

Invariant Natural Killer T Cells in Immune Surveillance and Tumor Immunotherapy: Perspectives and Potentials

Potent Anti-tumor effects of Combination therapy using Interleukin-23 and .ALPHA.-galactosylceramide

alpha-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor